Table 2 Significant changed pathways of combined analysis of proteins and metabolites by KEGG
From: Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
NO | Pathway name | Class | Names | q value |
|---|---|---|---|---|
1 | Glycolysis/gluconeogenesis | Protein | Fructose-1,6-bisphosphatase 1(FBP1) | 4.71E−02 |
Protein | Fructose-bisphosphate aldolase B(ALDOB) | 2.36E−06 | ||
Protein | 4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) | 2.24E−02 | ||
Metabolite | Hexose | 2.29E−06 | ||
2 | Pentose phosphate pathway | Protein | Fructose-1,6-bisphosphatase 1(FBP1) | 4.71E−02 |
Protein | Fructose-bisphosphate aldolase B(ALDOB) | 2.36E−06 | ||
Metabolite | Gluconolactone | 6.90E−07 | ||
Metabolite | Ribose | 1.58E−06 | ||
Metabolite | Hexose | 2.29E−06 |